HnRNP K protein is a heterogeneous nuclear ribonucleoprotein which has been proposed to be involved in the leukemogenesis of acute promyelocytic leukemia (APL), as well as in differentiation induced by all-trans retinoic acid (ATRA). We previously demonstrated a connection between SET and hnRNP K function in head and neck squamous cell carcinoma (HNSCC) cells related to splicing processing. The objective of this study was to characterize the participation of hnRNP K and SET proteins in ATRA-induced differentiation in APL. We observed higher (5- to 40-fold) levels of hnRNP K and SET mRNA in APL patients at the diagnosis phase compared with induction and maintenance phases. hnRNP K knockdown using short-hairpin RNA led to cell death in ATRA-sensitive NB4 and resistant NB4-R2 cells by apoptosis with SET cleavage. In addition, hnRNP K knockdown increased granulocytic differentiation in APL cells, mainly in NB4-R2 with ATRA. hnRNP K knockdown had an effect similar to that of treatment with U0126 (an meiosis-specific serine/threonine protein kinase/ERK inhibitor), mainly in NB4-R2 cells. SET knockdown in APL cells revealed that apoptosis induction in cells with hnRNP K knockdown occurred by SET cleavage rather than by reduction in SET protein. Transplantation of NB4-R2 cells into nude mice confirmed that arsenic trioxide (ATO) combined with U0126 has higher potential against tumor progression when compared to ATO. Therefore, hnRNP K/SET and ERK are potential therapeutic targets for both antineoplastic leukemia therapy and relapsed APL patients with ATRA resistance.
HnRNP K protein is a heterogeneous nuclear ribonucleoprotein that acts as a transcriptional regulator by binding directly to DNA and RNA through the homologous domain K, which acts as a nucleic acid-regulated docking platform [1,2]. This protein, present in the nucleus, cytoplasm, and mitochondria, is involved in the regulation of gene expression, acting on transcription, RNA shuttling, RNA splicing, and translation processes [1]. Furthermore, hnRNP K has been considered as a prognostic marker in various types of cancer, including colorectal cancer [3], HNSCC [4], and chronic myeloid leukemia (CML) [5,6]. Besides that, its involvement in the leukemogenesis of acute promyelocytic leukemia (APL) has been proposed, as well as in the differentiation induced by all-trans retinoic acid (ATRA) [7].

Extracellular signal-regulated kinases (ERK1/2 proteins) belong to the mitogen-activated protein kinase (MAPK) family and regulate the activation of several cellular processes such as proliferation, cell differentiation, and survival, upon activation by numerous mitogen ligands. As MAPK pathway often presents deregulated in cancer, the components of this cascade have been proposed as targets in antineoplastic therapy [8]. The interaction of the hnRNP K protein with other proteins is also regulated via phosphorylation by MAPK/ERK pathway [9]. ERK inhibitor has demonstrated effect on the decrease in hnRNP K levels in CML, suggesting an antitumoral potential [10].

Recently, our group has demonstrated a connection between SET and hnRNP K function in HNSCC cells related to splicing processing [11]. The SET gene was originally identified as a component of the SET-CAN fusion gene in acute undifferentiated leukemia. SET, a 39 kDa protein, is known to be an endogenous inhibitor of phosphatase 2A subunit C (PP2A) [12,13]. However, SET is a multifunctional protein that participates in the response to oxidative stress [14], autophagy [15], DNA damage repair [16], apoptosis [17], cell migration [18], cell cycle control [19], and chromatin remodeling [20]. SET overexpression, reducing PP2A activity, has been reported and associated with a poor prognosis in chronic lymphocytic leukemia of B [21], CML [22], AML [23] cells, and other types of cancer [15,24].

In APL, the oncogene promyelocytic leukemia-retinoic acid receptor alpha genes (PML-RARA), resulting from reciprocal translocation t(15,17), leads to the compromise of granulocytic differentiation and genetic stability by directly interfering in the transcriptional regulation of RARA and PML, respectively [25]. ATRA promotes granulocytic differentiation restoring transcriptional activation of RARA target genes that are involved in cellular differentiation and by PML-RARα degradation, but the isolated therapy with ATRA leads to transient remission of disease [26], suggesting involvement of other mechanisms in the self-renewal of APL cells. Other molecular variables such as CCAAT enhancer-binding protein alpha (C/EBPα) and MYC, for example, onset of an occurrence of PML-RAR, have already been demonstrated in APL and associated with the leukemogenesis of this type of leukemia. The combination of ATRA with anthracycline chemotherapy is the mainstay treatment in some cases for APL, which promotes complete remission in 90% of cases and long-term disease-free status in 85% [27,28]. However, the differentiation syndrome [29,30] and resistance to ATRA [31,32] observed in patients interfere with the treatment. Thus, additional searches for new therapeutic targets are required.

After the demonstration that hnRNP K and SET are overexpressed in the APL patients compared with controls, in the present study we knocked down these proteins in both ATRA-sensitive (NB4) and ATRA-resistant (NB4-R2) cell lines by short-hairpin RNA interference (shRNA) and assessed their involvement in ATRA-induced cell differentiation, as well as their contributions to the maintenance and survival of leukemic cells. Besides, we showed the potential of an ERK inhibitor as a putative APL chemotherapy combined with arsenic trioxide (ATO).

Results

HNRNPK and SET mRNAs in APL patients

HNRNPK and SET mRNAs were measured by quantitative real-time PCR (qRT-PCR) in bone marrow (BM) samples from APL patients. Two transcripts, each encoding isoform a and b proteins of each gene, were analyzed. mRNA levels were compared at diagnosis (DP), postinduction (PIP), and maintenance phase (MP) for each patient. The hnRNP K and SET mRNAs were expressed 5- to 40-fold higher in DP compared with PIP and MP (Fig. 1A,B). Patient 5 (P5) suffered a relapse during MP of treatment, which was accompanied by an increase in the expression of both genes, mainly HNRNPK (Fig. 1A,B). The data suggest a relationship between the levels of both genes in the APL leukemogenesis as well as during the treatment of the same patient.

Next, we analyzed the distribution of SET and hnRNP K proteins in NB4 cells (ATRA-sensitive cell line) by using immunofluorescence assay and
microscopy (Fig. 1C). The colocalization of the proteins was lost when the cells were incubated with ATRA. Besides, this was accompanied by a slight reduction in SET protein and none apparent alteration in hnRNP K protein level when we analyzed by western blot (as shown in Fig. 5C). It reinforced our

Fig. 1. HnRNP K and SET were overexpressed in the BM of APL patients compared with BM of healthy individuals. (A) The gene expression of HNRPNK and (B) SET was determined by qRT-PCR in samples of patients \( n = 7 \) during DP of APL, induction (PIP) and MP of treatment, compared with BM samples from healthy individuals \( n = 2 \). Relative mRNA expression levels were calculated by the \( 2^{-\Delta\Delta CT} \) method; \( \beta \)-globin was used as the housekeeping gene. Data are reported as fold change in each phase (DP/IP/MP) compared with BM. Error bars represent SD of experiments performed in triplicate. (C) Confocal microscopy showing hnRNP K (green) and SET (red) proteins staining before (CTRL) and after ATRA treatment in NB4 cells. Nuclei were stained by DAPI (blue). Fluorescence overlapping is shown in yellow. Scale bar indicates 20 \( \mu \)m.
results in patient samples and our hypothesis on a potential crosstalk between hnRNPK and SET in ATRA-induced differentiation; consequently, their deregulations may have implications in ATRA resistance mechanisms. In addition, there are studies reporting each protein individually in leukemia [4,5,33,34]. Then, we selected the ATRA-sensitive cell line NB4 and the ATRA-resistant cell line NB4-R2, which are PML-RAR fusion gene positive (Fig. 2), as a model for our study.

HnRNPK is required for the survival and maintenance of leukemic cells

Initially, we confirmed that hnRNPK is an essential protein for APL cell survival and proliferation by using short-hairpin RNA for hnRNPK (sh_K; Fig. 3A). Besides, microscopic analysis showed the presence of apoptotic bodies in both NB4 and NB4-R2 cells with hnRNPK knockdown (Fig. 3B). Accordingly, we analyzed proteins related to survival [procaspase-3 and Bcl-2-like protein 1 (Bcl-xl)], differentiation (PML-RARa, ERK1/2, PU.1, C/EBPα), and hnRNPK function [SET, histone deacetylase 1 (HDAC1)]. Interestingly, a reduced level of the procaspase-3 and Bcl-xl proteins was accompanied by SET cleavage in APL sh_K cells, suggesting cell death by apoptosis. Notably, ERK1/2 levels were increased while the levels of PML-RARa (oncoprotein), HDAC1, PU.1, and C/EBPα (isoforms p42 and p30 kDa) were decreased (Fig. 3C). The increase in SET cleavage (bands below 39 kDa) in sh_K cells was confirmed using a monoclonal antibody against SET (Sigma-Aldrich Inc., Saint Louis, MO, USA). Besides, the antibody recognized other cleaved SET forms, namely ~35, ~28, ~20, and ~18 kDa (Fig. 3D). These results suggest that hnRNPK levels in NB4 and NB4-R2 cell lines are directly correlated with cell survival and differentiation signaling.

Initially, we selected NB4 and NB4-R2 cells with the shRNA-negative control (NC) and shRNA for hnRNPK (sh_K) with 0.5 µg·mL⁻¹ puromycin, but the hnRNPK knocked down cells were lost within a few days. Then, a cell growth curve was obtained after transduction under different puromycin concentrations for both cell lines to establish the ideal conditions for hnRNPK knockdown with enough number of live cells (data not shown). The concentrations of puromycin selected were 0.15 µg·mL⁻¹ for NB4 and 0.2 µg·mL⁻¹ for NB4-R2 (Fig. 4A). hnRNPK knockdown (sh_K), combined with ATRA treatment, promoted a higher loss of viability in NB4-R2 cells than in NB4 cells (Fig. 4B). Of note, cell death observed in sh_K cells was followed by increased cell differentiation, as assessed by CD11b labeling (Fig. 4C,D). These results provide evidence that the reduction in hnRNPK levels can modify the status of the NB4-R2 cell line regarding ATRA-sensitive behavior. They indicate that hnRNPK is an important protein involved in the resistance to ATRA-induced differentiation and APL cell survival.

MEK inhibitor reduces hnRNPK protein levels and mimics hnRNPK knockdown in APL cell lines

To assess a relationship between the ERK signaling and hnRNPK functions in APL, we used U0126, a MEK1/MEK2 inhibitor. The treatment with U0126 promoted a significant loss of cell viability in both APL cells (Fig. 5A,B). However, NB4 cells under ATRA + U0126 presented higher viability than NB4-R2, suggesting a potential U0126 sensitivity associated with an undifferentiated APL behavior. Both NB4 and NB4-R2 cell lines presented the same profile regarding hnRNPK protein levels, that is, a decrease in hnRNPK in the presence of the inhibitor (Fig. 5C,D). Furthermore, for both cells, Bel-xl levels were decreased and SET was cleaved in the presence of either U0126 or U0126 associated with ATRA, as observed in sh_K cells. These data indicate that the effect of hnRNPK protein knockdown could be mimicked by blocking MEK/ERK signaling, since hnRNPK K phosphorylation is regulated by MEK/ERK. The STAT3 protein, a downstream target by ERK, was reduced in the presence of U0126 and ATRA (Fig. 5C,D). It suggests that NB4-R2 (ATRA-resistant cells/undifferentiated cells) is dependent on hnRNPK K protein/ERK signaling to survive. It is supported by our result showing a reduced NB4 cell viability under U0126 (alone) but its recovery under ATRA + U0126.
MEK inhibitor, in combination with arsenic trioxide therapy, leads to smaller tumors in a human NB4-R2 xenograft murine tumor model

When the effect of ATO, a clinical approved treatment, was compared to U0126 and U0126 combined with ATO in the viability of NB4-R2 cells in vitro, there was higher cell death in cells exposed to U0126 + ATO (Fig. 6A). In view of the positive results obtained with ATO plus U0126 in NB4-R2 cells, an NB4-R2 xenograft tumor model was used. The groups were as follows: U0126 (n = 5, U0126 2.5 mg kg⁻¹), ATO (n = 5, 2.5 mg kg⁻¹), and U0126 + ATO groups (n = 5, U0126 2.5 mg kg⁻¹ + ATO 2.5 mg kg⁻¹). The treatment started 4 days after cell transplantation every 48 h. Animals were euthanized on the 17th day of the experiment, and tumors were extracted and weighed (Fig. 6B). NB4-R2 xenograft tumors from nude mice treated with the U0126 + ATO combination were smaller (Fig. 6B) than those
receiving monotherapy, indicating that the combined treatment was more efficient. Histological analysis of tumor tissues after hematoxylin and eosin (H&E) staining showed that the tumors were extremely hemorrhagic, and the immunohistochemistry for Ki67, a proliferation marker, showed areas with low proliferation (without Ki67 staining) and cell death (necrosis; Fig. 6C).

**SET knockdown facilitates cell differentiation in ATRA-resistant cells**

To understand how SET protein level participates in ATRA resistance and its relationship with hnRNP K in APL, we analyzed by immunoblotting hnRNP K and other proteins involved in promyelocyte differentiation. ShSET in association with ATRA showed lower level of PML and PML-RARα proteins in NB4 cells and lower PML-RARα in NB4-R2 cells compared with shNC (Fig. 7A,B). Surprisingly, shSET NB4 cells under ATRA treatment showed a lower level of PU.1 protein compared with sh NC cells, suggesting a potential function of SET in PU.1 expression (Fig. 7A). Moreover, NB4-R2 cells with shSET showed a reduction in C/EBPα and c-myc levels compared with sh NC cells, suggesting a SET function in granulopoiesis and proliferation. In addition, NB4-R2 shSET cells showed higher levels of PU.1 and C/EBPα.

**Fig. 4.** HnRNP K knockdown leads to the loss of NB4 and NB4-R2 cell viability, favors cell differentiation, and sensitizes ATRA-resistant cells. (A) NB4 and (B) NB4-R2 cells were transduced with short-hairpin RNA to hnRNP K. The selection of the cells after transduction was performed with 0.15 μg·mL⁻¹ puromycin for NB4 cells and 0.2 μg·mL⁻¹ for NB4-R2. The reduction in hnRNP K was confirmed by immunoblotting using anti-hnRNP K. ATRA (1 μM) treatment was performed as previously described. After selection with puromycin for 96 h, cell viability assays were performed by the PI incorporation method and analyzed by flow cytometry. (C) NB4 and (D) NB4-R2 (1 x 10⁵) cells were incubated with anti-CD11b PE, and cellular differentiation was analyzed by flow cytometry as the percentage of CD11b positive cells. Data are presented as mean ± SD of two independent experiments performed in triplicate. CTRL = control. NC, short-hairpin RNA-NC. Statistical analysis was performed by one-way ANOVA followed by the Bonferroni post-test, * (P < 0.001) NC compared with sh hnRNPK, and ** (P < 0.001) compared with the control (CTRL); & (P < 0.001) Puro+ATRA compared with ATRA.
under ATRA induction (Fig. 7B). Finally, we analyzed proliferation in shSET APL cells and both cells reduced proliferation (Fig. 7C).

Discussion

This study is the first to demonstrate both the hnRNP K and SET profiles in the same APL patients and in cell lines simultaneously, as well as their involvement in ATRA-induced differentiation of leukemic promyelocytes and to propose an ERK inhibitor combined with ATO as a potential new therapy for APL patients.

The accumulation of hnRNP K and SET mRNA in APL patient samples, during the diagnostic phase, in addition to the reduction in hnRNP K and SET during the chemotherapy phase, suggests not only the involvement of both genes in the leukemogenesis of APL, but also that hnRNP K and SET could be useful as prognostic indicators or treatment response biomarkers.

hnRNP K and SET levels were reduced in all patients during IP and MP, except for patient P5 who showed a relapse and higher levels than those detected during DP, mainly hnRNP K, associated with the molecular recurrence of PML-RARα. According to previous reports, increased gene expression and protein levels of hnRNP K and SET are frequent events in several types of cancer and they have been proposed to be prognostic markers in leukemia, mainly in CML, increasing during a blast crisis [5,6,22,23,35]. A correlation of mRNA hnRNP K and SET levels in patients’ samples during distinct APL phases suggests crosstalk between these genes in APL. Colocalization of hnRNP K with SET protein was detected by immunofluorescence microscopy in NB4 and NB4-R2, but it disappeared during cellular differentiation induced by ATRA, supporting a connection between them during leukemogenesis in APL. Crosstalk between hnRNP K and SET in HNSCC was previously demonstrated by our group [36]. Specifically, SET accumulation in HNSCC regulates and interacts with hnRNP K.
increasing its binding to nucleic acids, as demonstrated for Bcl-xS, an anti-apoptotic gene [11].

High levels of hnRNP K and SET in APL samples indicate that these proteins participate in the granulopoiesis process. hnRNP K has been reported to be crucial to embryogenesis in mice [36] and to be associated with several functions from gene expression regulation to protein translation [1]. Furthermore,

**Fig. 6.** *In vivo* effect of U0126 in association or not with ATO using a NB4-R2 xenograft murine tumor model. (A) NB4-R2 cells (2 × 10⁶ cells·mL⁻¹ in six-well plates performed in duplicate) were incubated with 10 µM U0126 and 1 µM ATO for 96 h, combined, and isolated (CTRL). Cell viability assay in NB4-R2 was performed by the PI incorporation method. Cells were incubated with 1 µg·mL⁻¹ PI immediately before reading and analyzed by flow cytometry (BD FACSCalibur). Data are reported as mean ± SD of three independent experiments performed in duplicate. Statistical analysis was performed by one-way ANOVA (one-dimensional analysis of variance followed by the Bonferroni post-test), ****(P < 0.001). (B) NB4-R2 cells (5 × 10⁶) were transplanted in 8-week-old Balb/C male nude mice on the back of the animal bilaterally. Animals were randomly divided into groups: U0126 (n = 5, U0126 2.5 mg·kg⁻¹), ATO (n = 5, 2.5 mg·kg⁻¹), and U0126 + ATO (n = 5, U0126 2.5 mg·kg⁻¹ + ATO 2.5 mg·kg⁻¹). Animals in each group were identified from 1 to 5 by labeling the ear. Treatment was started on the fourth day after cell transplantation and performed every 48 h for a total of six applications. Animals were euthanized on the 17th day of the experiment. At autopsy, tumors were excised and weighed; the results are reported in mg. Data are reported as mean ± SD. Statistical analysis was performed by one-way ANOVA followed by the Bonferroni post-test, #*(P < 0.05). (C) H&E staining of tissues indicated hemorrhagic and necrosis areas. Immunohistochemistry (IHC) was performed using an anti-Ki67, and the complexes were visualized by 3, 3-diaminobenzidine staining. The tissue samples were counterstained by Harry’s hematoxylin and analyzed under a light field microscope. Scale bars indicate 100 µm (H&E) and 50 µm (IHC).
Hematopoietic stem cells from haploinsufficient animals are able to form hematological neoplasms in transplanted mice, suggesting hnRNP K as a tumor suppressor [36]. However, a previous work showed that hnRNP K overexpression is related to the progression of CML and proposed the protein as a potential therapeutic target [5]. Indeed, the role of hnRNP K in diverse cell cancer types is more complex and needs to be defined.

Similarly, SET involvement in hematopoiesis is unknown, except for the fact that SET is regulated by transcription factors involved in hematopoietic differentiation in AML, such as RUNX1 and GATA-2 [37]. Since the expression of hnRNP K and SET was higher in APL patients, the knockdown of hnRNP K and SET proteins in APL cells was adopted as our model to study ATRA-induced differentiation.

The hnRNP K knockdown in NB4 and NB4-R2 cells reduced c-Myc protein and proliferation. In this regard, it has been reported that hnRNP K regulates the activation of transcription and translation of c-Myc [38,39], which is directly involved in cell proliferation and cell cycle progression [40], and it is a potential therapeutic target in AML via apoptosis induction [41]. The cell death induced by hnRNP K knockdown in NB4 and NB4-R2 cells is promoted at least in part by the reduction in Bel-xL protein (anti-apoptotic) and procaspase-3, suggesting apoptosis induction [42]. Moreover, another finding associated with cell death was the cleavage of SET protein in ~37, ~28, ~20, and ~18 kDa. Similar SET fragmentation into ~28 kDa and ~22 kDa and ~20 kDa has already been reported and is associated with apoptosis [17,43].

Remarkably, the selection of APL cells with shRNA for hnRNP K using a low concentration of puromycin efficiently reduced hnRNP K levels accompanied by cell death, an effect amplified mainly in NB4-R2 cells by treatment with ATRA. The decrease in cell viability

Fig. 7. SET knockdown led to an alteration in the promyelocyte differentiation pathway and proliferation loss. Cells were transduced with shRNA to SET and selected with 0.5 µg·mL⁻¹ puromycin for 15 days. (A) After establishing shSET NB4 and (B) shSET NB4-R2, cell lines were treated with ATRA (1 µM) as previously described. The proteins were analyzed by using antibodies for SET, hnRNP K, c-Myc, PML/PML-RARα, PML, ERK1/2, and GAPDH. (C) For the growth curve, 5 x 10⁴ cells·mL⁻¹ were seeded into a 24-well plate, in triplicate, and counting was performed every 24 h for 96 h using the Trypan Blue exclusion method. Data are reported as mean ± SD of two independent experiments performed in triplicate. Statistical analysis was performed by one-way ANOVA followed by the Bonferroni post-test, *P < 0.05, **P < 0.01.
was accompanied by a significant increase in cell differentiation, indicating that hnRNP K knockdown sensitizes both ATRA-sensitive and ATRA-resistant cells. We propose that cell differentiation occurred, at least partly, by the decrease in PML-RARα oncoprotein and HDAC1 corepressor. The decrease in PML-RARα levels is a critical event to restore the transcription of RARα target genes [44]. During granulocyte differentiation, C/EBPα levels decrease in the early stages and PU.1 levels increase in the late stages under ATRA treatment [45]. Our results showed a decrease in both proteins when hnRNP K protein is knocked down. The decrease in PU.1 can be explained by the fact that hnRNP K interacts with PU.1 during granulocytic differentiation induced by ATRA [46]. Therefore, in hnRNP K knockdown cells, the differentiation is activated by an alternative pathway.

This novel finding stimulated us to test a MEK1/2 inhibitor (U0126) to block hnRNP K phosphorylation. U0126 reduced hnRNP K activity and promoted cell death in NB4 and NB4-R2 cells. Strikingly, this effect was accompanied by the cleavage of SET protein. These observations suggest an effect of U0126 similar to hnRNP K knockdown in APL cells, especially in cell viability. A correlation of hnRNP K and MAPK levels has been reported in CML, suggesting that ERK may have therapeutic potential [10,47]. Based on the results obtained with the xenograft NB4-R2 tumor model, we propose that the association of U0126 with ATO could be an effective therapeutic strategy in patients with ATRA resistance.

Interestingly, SET knockdown in both cells showed a lower decrease in proliferation when compared to hnRNP K knockdown (sh K), supporting our hypothesis that loss of viability in sh K cells occurs by SET cleavage rather than by the reduction in SET protein. SET protein has been reported to be overexpressed in leukemia and other cancer types and associated with cell proliferation and survival [21,22,48,49]. Also, low cell proliferation in shSET cells was accompanied by a reduction in c-Myc, which in turn is directly involved in cell cycle proliferation and progression [40]. Another new finding is ATRA response in NB4 shSET cells was accompanied by decreased PML-RARα, PU.1, and C/EBPα levels. Therefore, hnRNP K protein depends on SET protein, so that a decrease in SET implies a decrease in hnRNP K activity as evidenced by PU.1 reduction in shSET cells. These results need to be explored in the future to understand the mechanism by which SET and hnRNP K are regulating PU.1.

In conclusion, we propose that (a) hnRNP K is a negative regulator of promyelocytic differentiation in APL by maintaining the stability of PML-RARα, (b) this contributes positively to cell survival and maintenance through regulation of c-Myc, Bcl-xL, and SET proteins, (c) ERK signaling is essential for leukemogenesis and viability, by regulating hnRNP K protein (demonstrated by the treatment with U0126), and (d) hnRNP K and SET are regulating PU.1 expression/levels. Besides, because the inhibition of ERK signaling was associated with positive regulation of SET cleavage, we proposed the ERK/hnRNPK/SET signaling as target for APL and ATRA-induced differentiation. Further studies will be needed to assess the full mechanism of hnRNP K and SET in granulopoiesis and to examine their potential as molecular markers in APL patients.

Material and methods

Patients

Samples of seven patients (three women and four men) with a confirmed diagnosis of APL by qRT-PCR for PML/RARA and submitted to IC-APL protocol treatment [50] were used. Samples were obtained at diagnosis, after induction, and during maintenance treatment. BM from APL patients and healthy donors (n = 2) was obtained from the biorepository of the Hematology Laboratory (the Ethical Committee for Human Research approved the protocol number: Hospital da Clínicas de Ribeirão Preto/HCMPR/7147/2005, University Hospital of the Medical School of Ribeirão Preto, University of São Paulo (HCFMRP-USP). BM (BM; n = 2) from healthy donors was used as control. Biological samples from all individuals were collected after all patients, and healthy donors signed written informed consent form. The study was approved by the Committee for Ethics in Research on Human of the School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil (Ethical approved protocol number 1.255.749). The work complies with the Code of Ethics of the World Medical Association (Declaration of Helsinki; http://www.cirp.org/library/ethics/helsinki/).

Cell lines and culture conditions

The APL cells NB4 and NB4-R2 t(15,17), respectively, responsive and resistant to ATRA-induced differentiation therapy, were cultured in RPMI-1640 medium supplemented with 10% FBS (GIBCO, Thermo Fisher Scientific Inc., Walharn, MA, USA), 1% antibiotic + antimycotic (Sigma-Aldrich), in an incubator with a 5% CO2 humidified atmosphere, at 37 °C. NB4 and NB4-R2 cells were periodically treated with ATRA to assess their ability to differentiate (data not shown). The karyotype of NB4 and NB4-R2 cells confirmed the presence of t(15,17) (data not shown). HL-60 and KG-1a (American Type Culture Collection, Manassas, VA, USA), which did not present t(15,17), were cultured...
under the same conditions, but in Iscove's modified Dulbecco's medium in the presence of 20% FBS.

**Reagents**

ATRA, monoethanolate-specific inhibitor of MEK1 and MEK2 (U0126), propidium iodide (PI), Histopaque-1077, puromycin, and DMSO were purchased from Sigma-Aldrich. DMSO was used as a vehicle in ATRA-induced differentiation and the U0126 experiments.

**Induction of differentiation in APL cells by ATRA**

Treatment was performed with 1 μM ATRA (SIGMA-Aldrich) applied to 2.5 x 10^5 cells·mL⁻¹ for 96 h, and the rate of differentiation was measured by determining the number of cells labeled with CD11b conjugated to PE (BD Company, Franklin Lakes, NJ, USA) by flow cytometry. The assays were performed in triplicate.

**RNA extraction and quantitative real-time PCR**

RNA was isolated from both IC-APL (International Consortium on APL) samples and cell lines using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to manufacturer’s instructions. RNA integrity was determined with a 2100 Bioanalyzer (Agilent, Waldbronn, Germany) and quantified with a UV/VIS NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA). c-DNA synthesis was obtained using 500 ng RNA with the Go Script™ Reverse Transcription System (Promega, Madison, WI, USA). The PCR Master Mix reaction was performed using GoTaq® qPCR Master Mix (Promega). The oligonucleotides used for mRNA sequences from HNRNPK, SET, and β-GLOBIN genes and conditions are described in Table S1. Relative changes in gene expression from qRT-PCR experiments were calculated using the 2^−ΔΔCT (2^−(CT sample − CT sample housekeeping gene) − (CT calibrator − CT calibrator housekeeping gene)) method [51].

**Immunoblotting assay and antibodies**

The method is described as previously [24], and the antibodies were described in Table S2.

**Immunofluorescence analysis**

Immunofluorescence was performed as previously reported [24] by using primary antibodies against hnRNP K and SET proteins (Table S2). Anti-goat conjugated with DyLight®680 or an anti-mouse conjugated with Alexa 488 (Invitrogen). Nuclei were stained with DAPI. The digital images were obtained using a Leica TCS SP8 confocal laser scanning microscope (Leica Microsystems, Wetzlar, Alemania) using the 63× objective with 3× digital zoom. The scale bar was defined as 20 μm for images with 3× digital zoom.

**Assessment of cell viability and differentiation by flow cytometry**

Myeloid cell differentiation was determined in NB4 and NB4-R2 cells using the anti-CD11b PE (BD) and flow cytometry. Cell viability was assessed by PI (1 μg·mL⁻¹) staining and flow cytometry (BD FACSCalibur, San Jose, CA, USA). All assays were performed in triplicate.

**Plasmids and interference RNA**

Knockdown of hnRNP K or SET proteins was performed in NB4 and NB4-R2 cells using the MISSION short-hairpin RNA (shRNA) plasmid (Sigma-Aldrich). After screening using five shRNA sequences for the hnRNP K protein in APL cells, we selected for the assay a clone with the highest efficiency for the knockdown of the target protein (data not shown). The selected shRNA sequences were two nonmammalian targets as NC (pLKO.1puro, SHC202, and SHC002; SIGMA), human hnRNP K (sh3, clone 3-NM_002140.3; SIGMA), and human SET (shSET, NM_003011.1-467s1c1; SIGMA, TRCN0000063717). NB4 and NB4-R2 cells were transduced with the lentiviral particles constructed with the ViraPower™ Lentiviral Expression System (MISSION® Lentiviral Packaging Mix-Invitrogen) and HEK293FT (Life Tech, Thermo Fisher Scientific) according to the manufacturer’s protocol. After selection with 500 ng·mL⁻¹ puromycin, the extent of knockdown of hnRNPK and SET proteins in both APL cell lines was determined by immunoblotting.

**Cell growth curve**

According to the indicated time and conditions in each assay, the cell growth curve was constructed using the Trypan Blue exclusion assay.

**Panoptic staining**

For fast panoptic staining, 1 x 10^4 cells were washed in PBS 1× and spin down on a microscope slide by centrifugation at 200 g for 1 min at room temperature. The cells were stained following the manufacturer’s protocol (Laborclin, Pinhais, Paraná, Brazil). Briefly, the cells were incubated for 5 s in solutions #1, #2, and #3 and subsequently washed with deionized water. Microscopy analyses were performed in a brightfield, PlasDIC, phase contrast, and fluorescence AXIOVERT 40 CFL (ZEISS, Gotting, Germany) at 400× original magnification.

**Xenograft tumor model using NB4-R2 cells and immunohistochemistry**

A human NB4-R2 xenograft tumor model in athymic nude mice (Balb/C) was used as previously described [24]. NB4-R2 wild-type cells (5 x 10^6) were transplanted to induce
the tumors bilaterally. The animal experimentation was approved and conducted according to the ethical conduct outlined in the Care and Use of Animals for Experimentation of the School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo (protocol number no 16.1.90.60.0). At autopsy, tumors were weighed and fixed in 4% neutral buffered formalin for 24 h and then in 70% ethanol until the beginning of histological processing. Six-micrometer tissue sections were obtained. Staining by H&E was performed and analyzed under a light field microscope at 100× magnification. For immunohistochemistry, antigen recovery was performed in a microwave oven for 30 min with citrate buffer. Endogenous peroxidase blockade was done with 3% hydrogen peroxide for 15 min. Slides were incubated with Ki67 primary antibody (Abcam, Cambridge, MA, USA, ab15580, 1:100 in PBS-T + 3% BSA) for 16 h at 4 °C in a humid chamber. LSAB (Dako Denmark A/S, Agilent Technologies Inc., Santa Clara, CA, USA) was used as the universal secondary antibody, and DAB was used as the chromogen. The tissue samples were counterstained by immersion in Harry’s hematoxylin.

**Statistical analysis**

Statistical analysis was performed using GRAPHPAD PRISM software version 5.0 (GraphPad Software Inc., La Jolla, CA, USA). The tests used are indicated when each result is reported.

**Acknowledgements**

We thank Priscila Santos Scheucher and Ana Silvia Gouvêa de Lima, Laboratory of Hematology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil, for technical support. This research was supported by the Research Foundation of São Paulo State/FAPESP (grant: # 2016/19103-2, 2013/10898-4, and 2013/08135-2; scholarship: # 2013/00374-8 and 2013/01355-7), CAPES (001), and CNPq Brazil.

**Conflict of interest**

The authors declare no conflict of interest.

**Data accessibility**

All supporting data are included in the manuscript and as supplementary information.

**Author contributions**

KSP, EMR, and AML conceived and designed the project; KSP, RNG, LBF, CBG, MSB, and VMA acquired the data; KSP, EMR, and AML analyzed and interpreted the data; KSP and AML wrote the paper; LJG, EMR, and AML revised the paper.

**References**

1. Bomsztyk K, Denisenko O and Ostrowski J (2004) hnRNP K: one protein multiple processes. BioEssays 26, 629–638.

2. Leopoldino AM, Carregaro F, Silva CHTP, Feitosa O, Mancini UM, Freitas JM and Tajara EH (2007) Sequence and transcriptional study of HNRPK pseudogenes, and expression and molecular modeling analysis of hnRNP K isoforms. Genome 50, 451–462.

3. Wang F, Zhang P, Shi C, Yang Y and Qin H (2012) Immunohistochemical detection of HSP27 and hnRNP K as prognostic and predictive biomarkers for colorectal cancer. Med Oncol 29, 1780–1788.

4. Matta A, Tripathi SC, DeSouza LV, Grigull J, Kaur J, Chauhan SS, Srivastava A, Thakar A, Shukla NK, Duggal R et al. (2009) Heterogeneous ribonucleoprotein K is a marker of oral leukoplasia and correlates with poor prognosis of squamous cell carcinoma. Int J Cancer 125, 1398–1406.

5. Du Q, Wang L, Zhu H, Zhang S, Xu L, Zheng W and Liu X (2010) The role of heterogeneous nuclear ribonucleoprotein K in the progression of chronic myeloid leukemia. Med Oncol 27, 673–679.

6. Zhang J, Jin Z, Du Q, Li R, Yao F, Huang B, Xu N, Xu L, Luo X and Liu X (2012) Analysis of altered proteins related to blast crisis in chronic myeloid leukemia by proteomic study. Int J Lab Hematol 34, 267–273.

7. Harris MN, Ozpolat B, Abdi F, Gu S, Legler A, Mawuenyega KG, Tirado-Gomez M, Lopez-Berestein G and Chen X (2004) Comparative proteomic analysis of all-trans-retinoic acid treatment reveals systematic posttranscriptional control mechanisms in acute promyelocytic leukemia. Blood 104, 1314–1323.

8. Wagner EF and Nebreda AR (2009) Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9, 537–549.

9. Habelhah H, Shah K, Huang L, Ostareck-Lederer A, Burlingame AL, Shokat KM, Hentze MW and Ronai Z (2001) ERK phosphorylation drives cytoplasmic accumulation of hnRNP-K and inhibition of mRNA translation. Nat Cell Biol 3, 325–330.

10. Notari M, Neviani P, Santhanam R, Blaser BW, Chang JS, Galietta A, Willis AE, Roy DC, Caligiuri MA, Marcucci G et al. (2006) A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation. Blood 107, 2507–2516.

11. Almeida LO, Garcia CB, Matos-Silva FA, Curti C and Leopoldino AM (2014) Accumulated SET protein up-
regulates and interacts with hnRNPK, increasing its binding to nucleic acids, the Bel-xS repression, and cellular proliferation. *Biochem Biophys Res Commun* **445**, 196–202.

12 Adachi Y, Pavlakis GN and Copeland TD (1994) Identification and characterization of SET, a nuclear phosphoprotein encoded by the translocation break point in acute undifferentiated leukemia. *J Biol Chem* **269**, 2258–2262.

13 Li M, Makkinje A and Damuni Z (1996) The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. *J Biol Chem* **271**, 11059–11062.

14 Leopoldino AM, Squarize CH, Garcia CB, Almeida LO, Pestana CR, Sobral LM, Uyemura SA, Tajara EH, Silvio Gutkind J and Curti C (2012) SET protein accumulates in HNSCC and contributes to cell survival: antioxidant defense, Akt phosphorylation and AVOs acidification. *Oral Oncol* **8**, 1106–1113.

15 Almeida LO, Goto RN, Neto MPC, Sousa LO, Curti C and Leopoldino AM (2015) SET overexpression in HEK293 cells regulates mitochondrial uncoupling proteins levels within a mitochondrial fission/reduced autophagic flux scenario. *Biochem Biophys Res Commun* **458**, 300–306.

16 Almeida LO, Goto RN, Pestana CR, Uyemura SA, Gutkind S, Curti C and Leopoldino AM (2012) SET overexpression decreases cell detoxification efficiency: ALDH2 and GSTP1 are downregulated, DDR is impaired and DNA damage accumulates. *FEBS J* **279**, 4615–4628.

17 Madeira A, Pommet JM, Prochiantz A and Alliquant B (2005) SET protein (TAF1beta, I2PP2A) is involved in neuronal apoptosis induced by an amyloid precursor protein cytoplasmic subdomain. *FASEB J* **19**, 1905–1907.

18 Lam BD, Anthony EC and Hordijk PL (2013) Cytoplasmic targeting of the proto-oncogene SET promotes cell spreading and migration. *FEBS Lett* **587**, 111–119.

19 Canela N, Rodriguez-Vilarrupla A, Estanyol JM, Diaz C, Pujol MJ, Agell N and Bachs O (2003) The SET protein regulates G2/M transition by modulating cyclin B-cyclin-dependent kinase 1 activity. *J Biol Chem* **278**, 1158–1164.

20 Leung JW, Leitch A, Wood JL, Shaw-Smith C, Metcalfe K, Bicknell LS, Jackson AP and Chen J (2011) SET nuclear oncogene associates with microcephalin/MCPH1 and regulates chromosome condensation. *J Biol Chem* **286**, 21393–21400.

21 Christensen DJ, Chen Y, Oddo J, Matta KM, Neil J, Davis ED, Volkheimer AD, Lanasra MC, Friedman DR, Goodman BK *et al.* (2011) SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target. *Blood* **118**, 4150–4158.

22 Neviani P, Santanam R, Trotta R, Notari M, Blaser BW, Liu S, Mao H, Chang JS, Galletta A, Utani A *et al.* (2005) The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. *Cancer Cell* **8**, 355–368.

23 Cristóbal I, García-Orti L, Cirauqui C, Cortes-Lavaud X, García-Sánchez MA, Calasanz MJ and Odero MD (2012) Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia. *Haematologica* **97**, 543–550.

24 Sobral LM, Sousa LO, Coletta RD, Cabral H, Greene LJ, Tajara EH, Gutkind JS, Curti C and Leopoldino AM (2014) Stable SET knockdown in head and neck squamous cell carcinoma promotes cell invasion and the mesenchymal-like phenotype in *vitro*, as well as necrosis, cisplatin sensitivity and lymph node metastasis in xenograft tumor models. *Mol Cancer* **13**, 32.

25 Lallemand-Breitenbach V and de Thé H (2010) PML nuclear bodies. *Cold Spring Harb Perspect Biol* **2**, a000661.

26 Lallemand-Breitenbach V, Guillenmi MC, Janin A, Daniel MT, Degos L, Kogan SC, Bishop JM and de Thé H (1999) Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. *J Exp Med* **189**, 1043–1052.

27 Wang ZY and Chen Z (2008) Acute promyelocytic leukemia: from highly fatal to highly curable. *Blood* **111**, 2505–2515.

28 Sanz MA, Montesinos P, Rayón C, Holowiecka A, de la Serna J, Milone G, de Lisa E, Brunet S, Rubio V, Ribera JM *et al.* (2010) Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline chemotherapy: new features and improved results. *Blood* **115**, 5137–5146.

29 Leblebician H, DeAngelio DJ, Skirvin JA, Stone RM, Wadleigh M, Werner L, Neuberg DS, Bartel S and McDonnell AM (2013) Predictive factors for all-trans retinoic acid-related differentiation syndrome in patients with acute promyelocytic leukemia. *Leuk Res* **37**, 747–751.

30 Montesinos P, Bergua JM, Vellenga E, Rayón C, Parody R, de la Serna J, León A, Esteve J, Milone G, Debén G *et al.* (2009) Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. *Blood* **113**, 775–783.

31 Tomita A, Kiyoi H and Naoe T (2013) Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in acute promyelocytic leukemia. *Int J Hematol* **97**, 717–725.

32 Sanz MA, Fenaux P, Tallman MS, Estey EH, Löwenberg B, Naoe T, Lengfelder E, Döhner H,
hnRNPK and SET in APL/ATRA-induced differentiation

K. S. Padovani et al.

Burnett AK, Chen SJ et al. (2019) Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood 133, 1630–1643.

33 von Lindern M, van Baal S, Wiegant J, Raap A, Hagemeijer A and Grosveld G (1992) Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3’ half to different genes: characterization of the set gene. Mol Cell Biol 12, 3346–3355.

34 Arriazu E, Pippa R and Odero MD (2016) Protein phosphatase 2A as a therapeutic target in acute myeloid leukemia. Front Oncol 6, 78.

35 Perrotti D and Neviani P (2007) From mRNA metabolism to cancer therapy: chronic myelogenous leukemia shows the way. Clin Cancer Res 13, 1638–1642.

36 Gallardo M, Lee HJ, Zhang X, Bueso-Ramos C, Pageon LR, McArthur M, Multani A, Nazha A, Manshouri T, Parker-Thornburg J et al. (2015) hnRNPK is a haploinsufficient tumor suppressor that regulates proliferation and differentiation programs in hematologic malignancies. Cancer Cell 28, 486–499.

37 Pippa R, Dominguez A, Malumbres R, Endo A, Arriazu E, Marcotegui N, Guruceaga E and Odero MD (2017) MYC-dependent recruitment of RUNX1 and GATA2 on the SET oncogene promoter enhances PP2A inactivation in acute myeloid leukemia. Oncotarget 8, 53989–54003.

38 Takimoto M, Tomonaga T, Matunis M, Avigan M, Krutzsch H, Dreyfuss G and Levens D (1993) Specific binding of heterogeneous ribonucleoprotein particle protein K to the human c-myc promoter, in vitro. J Biol Chem 268, 18249–18258.

39 Evans JR, Mitchell SA, Spriggs KA, Ostrowski J, Bomsztyk K, Ostarek D and Willis AE (2003) Members of the poly (rC) binding protein family stimulate the activity of the c-myc internal ribosome entry segment in vitro and in vivo. Oncogene 22, 8012–8020.

40 Amati B, Littlewood TD, Evans GI and Land H (1993) The c-Myc protein induces cell cycle progression and apoptosis through dimerization with Max. EMBO J 12, 5083–5087.

41 Xia B, Tian C, Guo S, Zhang L, Zhao D, Qu F, Zhao W, Wang Y, Wu X, Da W et al. (2015) c-Myc plays part in drug resistance mediated by bone marrow stromal cells in acute myeloid leukemia. Leuk Res 39, 92–99.

42 Clem RJ, Cheng EH, Karp CL, Kirsch DG, Ueno K, Takahashi A, Kastan MB, Griffin DE, Earnshaw WC, Velluona MA et al. (1998) Modulation of cell death by Bcl-XL through caspase interaction. Proc Natl Acad Sci USA 95, 554–559.

43 Tanimukai H, Grundke-Iqbal I and Iqbal K (2005) Up-regulation of inhibitors of protein phosphatase-2A in Alzheimer’s disease. Am J Pathol 166, 1761–1771.

44 Bassi SC and Rego EM (2012) Molecular basis for the diagnosis and treatment of acute promyelocytic leukemia. Rev Bras Hematol Hepatol 34, 134–139.

45 Fiedler K and Brunner C (2012) The role of transcription factors in the guidance of granulopoiesis. Am J Blood Res 2, 57–65.

46 Nika E, Brugnoli F, Piazzi M, Lambertini E, Grassilli S, Bavelloni A, Piva R, Capitani S and Bertagnolo V (2014) hnRNPK in PU.1-containing complexes recruited at the CD11b promoter: a distinct role in modulating granulocytic and monocytic differentiation of AML-derived cells. Biochem J 463, 115–122.

47 Chang JS, Santhanam R, Trotta R, Neviani P, Eiring AM, Briercheck E, Ronchetti M, Roy DC, Calabretta B, Caligiuri MA et al. (2007) High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation. Blood 110, 994–1003.

48 Leopoldino AM, Sauriz CH, Garcia CB, Almeida LO, Pestana CR, Sobral LM, Uyemura SA, Tajara EH, Silvio Gutkind J and Curti C (2012) SET protein accumulates in HNSCC and contributes to cell survival: antioxidant defense, Akt phosphorylation and AVOs acidification. Oral Oncol 48, 1106–1113.

49 Leopoldino AM, Sauriz CH, Garcia CB, Almeida LO, Pestana CR, Polizello AC, Uyemura SA, Tajara EH, Gutkind JS and Curti C (2012) Accumulation of the SET protein in HEK293T cells and mild oxidative stress: cell survival or death signaling. Mol Cell Biochem 363, 65–74.

50 Rego EM, Kim HT, Ruiz-Argüelles GJ, Undurraga MS, MeR U, Jacomo RH, Gutiérrez-Aguirre H, Melo RA, Bittencourt R, Pasquinii R et al. (2013) Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. Blood 121, 1935–1943.

51 Schmittgen TD and Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3, 1101–1108.

Supporting information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Table S1. The oligonucleotides (primers) used for mRNA sequences in qRT-PCR assays.

Table S2. Antibodies used in the present study.